Use of antisecretory factors in the treatment and / or prevention of acute respiratory failure

By using anti-secretion factor (AF) proteins and their homologs or fragments, the problem of alveolar fluid accumulation and cardiovascular system damage in acute respiratory failure is solved, and lung function and cardiac output is achieved. The effect of volume increase.

CN112368014BActive Publication Date: 2024-11-19LANTMANNEN MEDICAL AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980043507.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-06-28
Filing Date
2019-06-26
Publication Date
2024-11-19
Estimated Expiration
2039-06-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively restore and regulate epithelial barrier function, especially in acute respiratory failure (ARF), resulting in alveolar fluid accumulation and cardiovascular system damage.

Method used

Using anti-secretion factor (AF) proteins and their homologs or fragments, restore and normalize epithelial barrier function through the form of pharmaceutically active salts or food supplements, reduce fluid accumulation in alveolar and interstitial tissues, and improve cardiac output.

Benefits of technology

It significantly reduces the accumulation of fluid in the alveoli and interstitial tissues, improves cardiac output, and the effect is significant within 1 hour and lasts for at least 4 hours without adverse side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112368014B_ABST
    Figure CN112368014B_ABST
Patent Text Reader

Abstract

The present invention relates to the use of antisecretory factor (AF) protein, its homologues and / or fragments thereof with equivalent functional activity, and / or pharmaceutically active salts of the above substances for restoring and / or normalizing epithelial barrier function for the treatment and / or prevention of acute respiratory failure. In particular, the present invention discloses the use of antisecretory factor (AF) protein, its homologues and / or fragments thereof with equivalent functional activity, and / or pharmaceutically active salts of the above substances for dissolving and / or normalizing the transfer of fluid across epithelial cell barriers, which has a significant impact on most patients with traumatic lung injury, such as, but not limited to, patients with abnormal accumulation of fluid in the alveoli and / or bronchioles, selected from patients with BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular pulmonary disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the use of antisecretory factor (AF) protein, its homologues and / or fragments thereof with equivalent functional activity, and / or pharmaceutically active salts of the above substances for restoring and / or normalizing epithelial barrier function in the pathogenesis of acute respiratory failure (ARF).

[0002] In particular, disclosed herein is the use of antisecretory factor (AF) protein, its homologues and / or fragments thereof having equivalent functional activity, and / or pharmaceutically active salts of the above substances in abrogating and / or normalizing the transfer of fluid across epithelial barriers, which has a significant impact on most patients with acute respiratory failure (e.g., patients with abnormal accumulation of fluid in the alveoli and bronchioles due to acute respiratory failure (ARF), including but not limited to: ARDS (acute respiratory distress syndrome) and IRDS (infant respiratory distress syndrome). Background Art

[0003] Epithelial Barrier

[0004] The linings of surfaces in and on the body (e.g., the skin, and mucosal membranes of the respiratory, lung, and gastrointestinal and urinary tracts) are an important line of defense against, for example, invasion by microorganisms and their products and abnormal flow and / or distribution of fluids and solutes.

[0005] Epithelial cells establish a barrier between the usually hostile external environment and the internal environment. However, the cell lining is also responsible for the absorption of fluids, solutes and nutrients and the secretion of a variety of products (including waste products) and activities that require a selectively permeable barrier. These functions place the epithelium at the center of interactions between, for example, the mucosal immune system and the luminal contents (including food antigens and microbial products, as well as enclosed cells and their interstitial fluid).

[0006] Immunocompetent cells, especially lymphocytes, are involved in maintaining the integrity of these epithelial barriers. They contribute to tolerance of commensal organisms that occupy these same sites as well as tolerance of immune responses to harmful organisms and their products.

[0007] The concept "epithelial barrier" is a general term for various groups of epithelial cells that cover or line all body surfaces, cavities and tubes. This can be illustrated by the epithelial cells lining the blood and lymphatic vessels, which are called endothelial cells. Epithelial cells are firmly attached to the underlying tissues and organs through the basement membrane. Epithelial cells mediate a wide range of activities, such as selective diffusion, uptake, absorption, secretion, physical protection and containment. A very important function of the epithelial barrier is the selective and precise separation of the lumen and the control of components such as liquids and solutes from the air.

[0008] Epithelial barrier function requires a continuous cell layer as well as junctions that seal the intercellular spaces between epithelial cells. Together with the plasma membrane, intercellular tight junctions are the major cellular determinants of epithelial barrier function. Disruption of tight junction architecture due to specific protein mutations or aberrant regulatory signaling can be both a cause and a consequence of disease.

[0009] In the lung, airway epithelial cells form a barrier to the air / gas outside, and are at the forefront of mucosal immunity. The epithelial apical junction complex is formed by a series of protein subunits that promote cell-cell adhesion and barrier integrity. The integrity of the airway epithelium of patients suffering from, for example, asthma or bronchitis is often destroyed, and the contact of epithelial cells-cells has an uncertain loss. Repair events can lead to the formation of undifferentiated, disturbed and dysfunctional cells. In addition, the damage to the barrier function of the airway epithelium strengthens the mucosal permeability of foreign bodies through the airway epithelium. Therefore, it is proposed that airway epithelial barrier dysfunction can have an important impact on, for example, asthma, because the structural epithelial barrier function is intertwined with the ability of the epithelium to regulate the immune system and be regulated by it.

[0010] Therefore, impaired epithelial barrier function has been associated with many disease states (e.g., intestinal, pulmonary, cardiovascular, and systemic). Unfortunately, most current clinical data are correlational, making it difficult to separate cause from effect when interpreting the significance of barrier loss. There are currently no FDA-approved drugs that target the epithelial barrier to repair, restore, and regulate it. In order to develop such therapies, a deeper understanding of both disease pathogenesis and barrier regulation mechanisms is necessary.

[0011] Acute respiratory failure (ARF)

[0012] The term "acute respiratory failure (ARF)" is used interchangeably herein with "acute lung injury", "traumatic lung injury" and "trauma-related lung injury", and encompasses acute respiratory distress syndrome (ARDS) (which is divided into mild, moderate and severe according to the severity of the condition). ARDS is caused by systemic disease and / or lung cell damage (such as, but not limited to, trauma). Lung cell damage may be caused by pneumonia, inhalation of toxic substances, accidents (such as falls, traffic accidents or penetrating trauma), mechanical ventilation, immune response, cardiovascular dysfunction or sepsis. Brain damage caused by hemorrhage, stroke and trauma is another cause. ARDS is associated with reduced alveolar fluid clearance (ALC) capacity, destruction of the alveolar epithelial barrier and increased capillary endothelial permeability, resulting in increased alveolar and bronchiolar fluid accumulation.

[0013] According to previous studies, it is claimed that the pathophysiology caused by trauma associated with acute lung injury may be different from that caused by non-trauma-induced lung injury. The plasma levels of biomarkers of lung epithelial and endothelial injury are significantly reduced in trauma patients, which have previously been found to be prognostic in acute lung injury. It is concluded that trauma patients tend to have less severe lung epithelial and endothelial injury on average than patients with other clinical risks of lung injury (see Calfee et al., 2007). Therefore, in patients with traumatic lung injury who suffer lung injury, it would be beneficial to increase the possibility of restoring and / or normalizing epithelial barrier function, regardless of the mechanism of injury.

[0014] In addition, ARF may also be caused by sepsis, other severe systemic inflammatory diseases and / or cardiovascular pulmonary and / or cerebral disorders. Therefore, the present invention also relates to the use of antisecretory factor (AF) proteins, homologues thereof and / or fragments thereof having equivalent functional activity, and / or pharmaceutically active salts thereof for restoring and / or normalizing epithelial barrier function in the pathogenesis of acute respiratory failure (ARF) in patients suffering from sepsis, systemic inflammatory diseases and / or cardiovascular pulmonary and / or cerebral disorders.

[0015] In addition, staying at high altitude can cause acute lung damage, just like drowning.

[0016] Acute respiratory distress syndrome (ARDS)

[0017] ARDS is characterized by noncardiac dyspnea, tachypnea, fluid accumulation in the alveoli, bilateral chest radiographic opacities, and hypoxemia refractory to oxygen therapy. It should be emphasized that, despite the destruction of the alveolar cell lining, approximately one-third of ARDS patients in the early stages of the disease do not have any significant excess fluid in the alveoli (Sakka 2013; Claesson et al., 2016; Huppert and Matthay, 2017).

[0018] ARDS is a common reason for hospital admission to the ICU (intensive care unit) due to respiratory failure with hypoxemia (severe illness, usually requiring mechanical ventilation). With few exceptions, steroids are not recommended for patients with ARDS. Rescue therapies reduce hypoxemia in patients who cannot maintain adequate oxygenation: recruitment maneuvers, prone positioning, inhaled nitric oxide, high-frequency oscillatory ventilation, and extracorporeal membrane oxygenation improve oxygenation, but, with the exception of prone positioning, their effects on mortality have not been proven. Restrictive fluid management to avoid harmful overload of lung fluid appears to be a favorable strategy, but there is no clear reduction in 60-day mortality.

[0019] Cardiogenic overload of the lungs with blood and fluid can lead to deleterious, life-threatening conditions that mimic ARDS.

[0020] Infant Respiratory Distress Syndrome

[0021] IRDS (Infant Respiratory Distress Syndrome) is a syndrome in premature infants caused by insufficient production of pulmonary surfactant and incomplete development of immature lung structure.

[0022] Bronchopulmonary dysplasia (BPD)

[0023] Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that affects newborns, especially premature infants and infants. It results from damage to the lungs caused by mechanical ventilation (such as, but not limited to, respirators) and long-term use of oxygen. Most infants recover from BPD, but some have long-term breathing difficulties.

[0024] ARF includes BPD, IRDS and ARDS, which is characterized by damage to the capillary epithelium and alveolar epithelium, associated with impaired drainage of fluid from the alveolar cavity and accumulation of protein-rich fluid inside the alveoli. Concomitantly, alveolar cells form and release pro-inflammatory substances, aggravating acute lung conditions. As a result, the epithelial barrier of injured patients is damaged, resulting in increased capillary permeability, hindering lung function, oxygenation, and compromising the systemic function of body organs and the cardiovascular system.

[0025] Acute lung injury (particularly ARDS and similar conditions) imposes a huge burden of disease, and despite advanced modern medical treatment, approximately 40% of patients die in hospital (Claesson et al., 2016; Huppert and Matthay, 2017). Various factors, including patient-related factors such as age and severity of disease, country level, socioeconomic status, ventilator management, and ICU organizational factors, contribute to these lung injury outcomes. Only a few treatment strategies have been shown to improve survival outcomes.

[0026] Antisecretory Factor (AF) Protein

[0027] Antisecretory factor (AF) is a 41 kDa protein that was originally described to provide protection against diarrheal disease and intestinal inflammation (reviewed in Lange and 2001). The antisecretory factor (AF) protein has been sequenced and its cDNA cloned a long time ago. The antisecretory activity seems to be mainly exerted by a peptide located between amino acid positions 35 and 50 on the antisecretory factor (AF) protein sequence, which contains at least 4 to 16 (e.g., 4, 5, 6, 7, 8 or 16) amino acids of the consensus sequence. Immunochemical and immunohistochemical studies have shown that the antisecretory factor (AF) protein exists and can also be synthesized by most tissues and organs in the body. Synthetic peptides (comprising an antidiarrheal sequence, i.e., at least the amino acid sequence shown in SEQ.ID.NO: 2, which is located in the consensus sequence) have been previously characterized (WO 97 / 08202; WO 05 / 030246; WO 2007 / 126364; WO2018 / 015379).

[0028] Antisecretory factor (AF) proteins and peptides have previously been disclosed to normalize pathological fluid transport and / or inflammatory responses following cholera toxin challenge, for example in the gut and central nervous system (WO 97 / 08202). Thus, in WO 97 / 08202, it has been proposed that foods and feeds having the ability to induce endogenous AF synthesis or increased uptake of AF can be used to treat edema, diarrhea, dehydration and inflammation. WO 98 / 21978 discloses the use of products having enzymatic activity in the production of foods that induce endogenous formation of antisecretory factor (AF) proteins. WO 00 / 038535 further discloses foods as such that are enriched with and / or naturally enriched with natural antisecretory factor (AF) proteins (NASPs).

[0029] Antisecretory factor (AF) proteins and fragments thereof have also been shown to improve the repair of neural tissue and the proliferation, apoptosis, differentiation and / or migration of stem and progenitor cells and cells derived therefrom in the treatment of conditions associated with cell loss and / or gain (WO 05 / 030246), and have also been shown to be effective in the treatment and / or prevention of intraocular hypertension (WO 07 / 126364) and in the treatment and / or prevention of compartment syndrome (WO 07 / 126363).

[0030] The present inventors have also shown that AF is able to monitor and / or beneficially influence the structure, distribution and various functions of lipid rafts, receptors and / or caveolae in membranes and can therefore be used to treat and / or prevent structural disorders and functional disorders of lipid rafts and / or caveolae in cell membranes (WO 07 / 126365).

[0031] The inventors have also been able to demonstrate that the same antisecretory factor (AF) proteins, peptides thereof and fragments thereof can interfere with the bioactivation of transmembrane protein ion channels (e.g. NKCC1 via FAK and CAP) and that they can therefore directly modulate the pathological activity of ion channels in pathological cells and / or perturbed cells, effectively normalizing the intracellular pressure and transmembrane protein function in said cells and thus allowing, for example, improved uptake of drugs used in cancer therapy (WO 2010 / 093324).

[0032] Furthermore, in WO 2014 / 096384, antisecretory factor (AF) proteins, peptides, homologues and / or fragments thereof are shown to be useful for symptomatic, curative and palliative treatment of glioblastoma.

[0033] The present invention relates to the surprising insight that in the pathogenesis of acute respiratory failure (ARF), antisecretory factors (AF) also restore and / or normalize epithelial barrier function, thereby for example significantly resolving fluid accumulation in the respiratory system while at the same time exerting beneficial effects on the cardiovascular system. Summary of the invention

[0034] The present invention discloses for the first time an antisecretory factor (AF) protein as shown in SEQ ID NO:1 (AF) and / or its homologues and / or fragments thereof having equivalent activity and comprising an amino acid sequence as shown in SEQ ID NO:2 (AF-6), and / or pharmaceutically active salts thereof, and / or foods and / or food supplements (which are enriched with and / or naturally enriched with the antisecretory factor (AF) protein and / or its homologues and / or fragments thereof) for use in restoring epithelial barrier function and / or endothelial barrier function and / or normalizing epithelial barrier function and / or endothelial barrier function, for the treatment, improvement and / or prevention of acute respiratory failure (ARF).

[0035] Herein, the ARF to be treated, improved and / or prevented is selected from the group consisting of IRDS, BPD, ARDS, acute pulmonary edema and interstitial pulmonary edema.

[0036] Therefore, the present invention relates to the use of an antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or its homologues and / or fragments thereof comprising the amino acid sequence shown in SEQ ID NO: 2 (AF-6), and / or pharmaceutically active salts thereof, and / or foods and / or food supplements (enriched with and / or naturally enriched with the antisecretory factor (AF) protein and / or its homologues and / or fragments thereof) for the preparation of a pharmaceutical composition for restoring epithelial barrier function and / or normalizing epithelial barrier function for the treatment and / or prevention of acute respiratory failure.

[0037] The present invention relates to the use of an antisecretory factor (AF) protein and / or a homologue and / or a fragment thereof and / or a food and / or a food supplement (enriched with and / or naturally enriched with said antisecretory factor (AF) protein and / or a homologue and / or a fragment thereof) for restoring and / or normalizing epithelial barrier function, wherein the epithelial cell barrier function is restored and / or normalized in patients suffering from acute respiratory failure.

[0038] The antisecretory factor (AF) protein and / or its homologue and / or its fragment and / or the pharmaceutically active salt of the above substances used according to the present invention can be formulated in a pharmaceutical composition comprising one or at least two or more antisecretory factor (AF) proteins and / or its homologue and / or its fragment and / or the pharmaceutically active salt of the above substances. Generally, the pharmaceutical composition also comprises a pharmaceutically acceptable excipient.

[0039] The present invention also relates to the use of a pharmaceutical composition comprising at least one antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or its homologues and / or fragments thereof comprising the amino acid sequence as shown in SEQ ID NO: 2 (AF-6), and / or pharmaceutically active salts of the above substances in restoring epithelial barrier function and / or normalizing epithelial barrier function in the pathogenesis of acute respiratory failure.

[0040] In addition, the antisecretory factor (AF) protein and / or its homologues and / or its fragments and / or the pharmaceutically active salts thereof used according to the present invention can be formulated as food and / or food supplements, which are enriched with and / or naturally enriched with the antisecretory factor (AF) protein and / or its homologues and / or its fragments.

[0041] The antisecretory factor (AF) protein and / or its homologue and / or its fragment, and / or the pharmaceutically active salt of the above substances, and / or the food and / or the food supplement (enriched with the antisecretory factor (AF) protein and / or its homologue and / or its fragment) used according to the present invention can be formulated for intravascular infusion or injection, for intraocular, intranasal, oral, topical, dermal, subcutaneous and / or systemic administration, for administration as a spray, aerosol, inhalation and / or by a nebulizer. It can be formulated for systemic administration to the blood at a dose of 0.1 μg to 100 mg per kg body weight per administration, preferably at a dose of 1 μg to 10000 μg per kg body weight per administration. The administration can be carried out in a single dose, multiple doses and / or multiple administrations per day.

[0042] The antisecretory factor (AF) protein and / or its homologues and / or fragments thereof, and / or pharmaceutically active salts thereof, and / or foods and / or food supplements (enriched with said antisecretory factor (AF) protein and / or its homologues and / or fragments thereof) used according to the present invention may be provided as egg yolks enriched with and / or naturally rich in antisecretory factors, for example, as egg yolks enriched with and / or having a high natural content of naturally occurring antisecretory factors (NASP), or as egg yolks having at least 0.05 ng / ml of an antisecretory factor (AF) protein fragment having an amino acid sequence as disclosed in SEQ ID NO: 3 (AF-16) and / or SEQ ID NO: 4 (AF-8). The egg yolk may be spray dried.

[0043] In one embodiment, a method for restoring and / or normalizing epithelial barrier function for the treatment and / or prevention of ARF is disclosed, wherein an antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or a homologue and / or fragment thereof comprising an amino acid sequence as shown in SEQ ID NO: 2 (AF-6), and / or a pharmaceutically active salt thereof, a pharmaceutical composition comprising the antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or a homologue and / or fragment thereof comprising an amino acid sequence as shown in SEQ ID NO: 2 (AF-6), and / or a pharmaceutically active salt thereof, and / or a food and / or food supplement (enriched with and / or naturally enriched with the antisecretory factor (AF) protein and / or a homologue and / or a fragment thereof) is administered to a mammal in need thereof. The mammal may be a human.

[0044] Therefore, the present invention relates to a method for treating, ameliorating, preventing and / or prophylactically treating acute respiratory failure, such as a method for treating and / or preventing ARF selected from the group consisting of IRDS, BPD, ARDS, acute ARDS, severe ARDS, acute pulmonary edema and interstitial pulmonary edema, wherein a sufficient amount of an antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or a homologue thereof and / or a fragment thereof comprising the amino acid sequence as shown in SEQ ID NO: 2 (AF-6), and / or a pharmaceutically active salt thereof, a pharmaceutical composition comprising the antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or a homologue thereof and / or a fragment thereof comprising the amino acid sequence as shown in SEQ ID NO: 2 (AF-6), and / or a pharmaceutically active salt thereof, and / or a food and / or a food supplement (enriched with and / or naturally enriched with the antisecretory factor (AF) protein and / or a homologue thereof and / or a fragment thereof) is administered to a mammal in need thereof. The mammal may be a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 : The setup of the laboratory during the experiment. Both deeply anesthetized pigs had tracheostomies and were connected to ventilators. The same critical care monitoring equipment for both groups can also be seen. The handling of the two animals was blinded to the personnel participating in the study, and the coding was not available until all experiments were completed. The core body temperature was checked and maintained at 38°C to 39°C.

[0046] Figure 2 : Photos of lungs taken 5 hours after injury and 4 hours after any treatment. Figure 2 B) shows the injured lung treated with vehicle, whereas the right lung ( Figure 2 A) from pigs that received 2 mg AF-16 per kg body weight. Figure 2 B) discloses that ALI 1 hour after vehicle infusion results in the formation of extensive atelectasis and hemorrhage, discoloring the lung tissue and making it appear dark. Only limited areas of the upper part of the vehicle-treated lung appear normal, indicating that the functional capacity of the vehicle lung is limited. In contrast, the right photo ( Figure 2 A) shows that both the left and right lobes appear nearly normal with minor scattered hemorrhages, demonstrating the protective effect of AF-16 infusion. The efficacy of AF-16 treatment is dramatically shown by the discoloration marks on the lungs of vehicle-treated (left) pigs, which is associated with the increase in EVLW content forcing the pig lungs against the sternal ribs.

[0047] Figure 3 : The key result is to demonstrate the dynamics of increased accumulation of extravascular lung water (EVLW) in pigs exposed to lung injury at different times (AF). As shown in the figure, the recorded values ​​are plotted against treatments at one hour (per hour) intervals. Timeline is related to treatment:

[0048] A: Baseline of animals prepared for the experiment before lung injury;

[0049] B: 1 hour after lung injury and just before AF-16 / vehicle infusion;

[0050] C: 1 hour after AF-16 / vehicle infusion;

[0051] D: 2 hours after AF-16 / vehicle infusion;

[0052] E: 3 hours after AF-16 / vehicle infusion;

[0053] F: 4 h after AF-16 / vehicle infusion;

[0054] The EVLW portion of both groups increased from approximately 320 mL at baseline within 1 hour after lung injury to approximately 500 mL. If the pigs were treated with vehicle (saline), the EVLW remained at this level for another 4 hours. In contrast, after exposure to repeated lung lavages and harmful ventilation, EVLW was significantly reduced by AF-16 treatment, from approximately 500 mL to 400 mL within 4 hours, with a highly significant effect (p<0.001) and a beneficial effect, disclosing a reduction of approximately 20%. This 100 mL change is functionally very beneficial and is critical for reducing the amount of fluid-filled lung area and improving blood oxygenation. EVLW was measured by the PiCCO method in 6 pigs with ARDS that were infused with 2 mg / kg bw (body weight) AF-16, while 6 ARDS pigs were infused with vehicle only. Treatment was coded to the researcher.

[0055] Figure 4 : The heart is closely related to the lungs in structure and function. Impaired lung function is associated with reduced cardiovascular function, as revealed by reduced cardiac output (CO), a sensitive and accurate measure of the level of cardiac function. Figure 4 The graph in Figure 2 shows that induced ALI in the six vehicle-treated pigs increased from a baseline of 4.2 L / min / m 2 At about 1L / min / m 2 The CO was impeded, corresponding to a decrease of about 25% that persisted for the next 4 hours. In contrast, infusion of 2 mg / kg AF-16 into 6 pigs 1 hour after ALI maintained CO at near-normal levels, which is critical for severe diseases such as ARDS and is considered highly relevant clinically. AF-16 infusion significantly (p<0.05) increased CO compared to that recorded in vehicle-treated animals, and the beneficial effect persisted for at least 4 hours. Treatment was coded to the investigator. DETAILED DESCRIPTION

[0056] Definitions and Abbreviations

[0057] abbreviation

[0058] IFP: interstitial fluid pressure;

[0059] PBS: phosphate buffered saline;

[0060] AF: antisecretory factor;

[0061] Full-length AF protein (as shown in SEQ ID NO: 1);

[0062] AF-6: a hexapeptide consisting of amino acids CHSKTR (as shown in SEQ ID NO: 2);

[0063] AF-16: a peptide consisting of amino acids VCHSKTRSNPENNVGL (as shown in SEQ ID NO: 3);

[0064] AF-8: a heptapeptide consisting of amino acids VCHSKTR (as shown in SEQ ID NO: 4);

[0065] Octapeptide IVCHSKTR (as shown in SEQ ID NO: 5);

[0066] Pentapeptide HSKTR (as shown in SEQ ID NO:6);

[0067] SPC: Specially processed cereals;

[0068] RTT: A method for measuring the standardized secretory response in the rat small intestine, as disclosed in SE 9000028-2 (Publication No. 466331) for measuring the content of AF (ASP);

[0069] ARF: acute respiratory failure;

[0070] ARDS: Acute respiratory distress syndrome;

[0071] IRDS: infant respiratory distress syndrome;

[0072] BPD: bronchopulmonary dysplasia;

[0073] SIRS: Systemic Inflammatory Response Syndrome;

[0074] Sepsis: An infection with systemic manifestations.

[0075] definition

[0076] Protein is a biomacromolecule consisting of amino acid residues linked together by peptide bonds. Proteins as linear polymers of amino acids are also referred to as polypeptides. Typically, proteins have 50 to 800 amino acid residues, so the molecular weight is about 6000 to about hundreds of thousands of daltons or larger. Small proteins are referred to as peptides, polypeptides or oligopeptides. In this article, the terms "protein", "polypeptide", "oligopeptide" and "peptide" are used interchangeably. Peptides can have very few amino acid residues, for example 2 to 50 amino acid residues (aa).

[0077] As used herein, a "pharmaceutical composition" refers to a composition comprising a therapeutically effective amount of an antisecretory factor (AF) protein, optionally in combination with a pharmaceutically active excipient (e.g., a carrier or vehicle). The pharmaceutical composition is formulated for an appropriate route of administration, which may vary depending on the patient's condition and other factors (e.g., age or preference). The pharmaceutical composition presents the active substance to the human or animal body after administration. The pharmaceutical composition may be in the form of, for example, tablets, pills, lozenges, capsules, stool pills, gels, solutions, etc., but is not limited thereto.

[0078] The term "pharmaceutically active salt" refers to a salt of an antisecretory factor (AF) protein, peptide or polypeptide, or a salt of a homologue and / or a fragment thereof, which salt may be any salt derived therefrom based on the so-called Hofmeiser series. Other examples of pharmaceutically active salts include trifluoroacetate, acetate and lysine chloride, but the present invention is not limited thereto.

[0079] The term "antisecretory" in the present context refers to inhibiting or reducing secretion and / or fluid shift. Thus, the term "antisecretory factor (AF) protein" refers to a class of proteins that are able to inhibit or reduce or otherwise regulate fluid shift and secretion in the body.

[0080] In this article, "equivalent activity" is used interchangeably with the term "equivalent functional activity" and refers to the biological effect of antisecretory factor (AF) proteins, peptides or polypeptides, or homologues, derivatives and / or fragments thereof, i.e., their ability to improve the therapy and / or treatment of ARF, for restoring and / or normalizing the epithelial barrier function in lung and / or systemic diseases. Standardized examples for testing and / or measuring such abilities are well known in the art. Examples are given in the experimental section of the present application (e.g., Example 1). In addition, the biological activity of antisecretory factor (AF) proteins, peptides or polypeptides, or homologues and / or fragments thereof according to the present invention can be tested, for example, in a standardized in vitro lung injury model, such as, but not limited to, in Caco-2 cells ATCC; [see, e.g., V Nicolas and V Lievin-Le moal: Infection & Immunity 2015; 83: 907-922]), wherein transcellular fluid exchange and / or movement is measured.

[0081] Herein, the terms "equivalent activity" and "similar biological activity" are used interchangeably.

[0082] In the context of the present invention, the terms "antisecretory factor protein", "antisecretory factor (AF) protein", "AF-protein", AF, or homologues thereof, or fragments thereof are used interchangeably with the terms "antisecretory factor" or "antisecretory factor protein" as defined in WO 97 / 08202, and refer to antisecretory factor (AF) proteins or peptides, or homologues thereof, and / or fragments thereof having antisecretory and / or equivalent functions and / or similar activities, or to modifications thereof that do not alter the function of the polypeptide. Therefore, it should be understood that "antisecretory factor", "antisecretory factor protein", "antisecretory peptide", "antisecretory fragment" or "antisecretory factor (AF) protein" in the context of the present invention may also refer to homologues or fragments thereof. These terms are all used interchangeably in the context of the present invention. In addition, in the context of the present invention, the term "antisecretory factor" may be abbreviated as "AF". In the context of the present invention, antisecretory factor (AF) protein refers to a protein having antisecretory properties as previously defined in WO 97 / 08202 and WO 00 / 38535. Antisecretory factors are also disclosed in, for example, WO 05 / 030246. The term antisecretory factor also means natural antisecretory factors (NASPs) in egg yolk enriched with and / or naturally enriched with antisecretory factors, as disclosed, for example, in SE 900028-2 and WO 00 / 38535 and in WO 2017 / 009004, as further described below. In addition, alternative names have been used for AF proteins in the literature.

[0083] "Medical food" in the context of this article refers to a food, a food supplement or a food for special dietary use, which is prepared with an antisecretory factor (AF) protein, or alternatively has the ability to induce the synthesis and / or activation of endogenous AF. The food may be any suitable food in a fluid or solid form (such as a liquid or powder), a bar, a cereal or any other suitable food. Examples of such substances can be found in WO 2017 / 009004, WO 0038535 and / or WO 91 / 09536.

[0084] A "nebulizer" in the present context refers to a medical device that delivers liquid medication to the respiratory tract in the form of a mist.

[0085] The term "aerosol" in the present context refers to a gaseous suspension of finely divided solid or liquid particles.

[0086] In the present context, the term "adjuvant" is used to describe a pharmacological agent and / or an immunological agent that modifies the action of other agents. An adjuvant in the present invention enhances or optimizes the recipient's use of an administered active substance, thereby minimizing the necessary amount of said substance.

[0087] The present invention relates to a novel method for eliminating and / or preventing disturbed and / or impaired epithelial barrier function for treating, improving and / or preventing acute respiratory failure.

[0088] In particular, the present invention relates to an antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or its homologues and / or fragments thereof having equivalent activity and comprising an amino acid sequence as shown in SEQ ID NO: 2 (AF-6), and / or pharmaceutically active salts thereof, and / or foods and / or food supplements (enriched in the antisecretory factor (AF) protein and / or its homologues and / or fragments thereof) for use in restoring epithelial barrier function and / or normalizing epithelial barrier function for the treatment, improvement and / or prevention of acute respiratory failure.

[0089] Epithelial barrier function

[0090] The diffusion barrier between the blood and alveolar gases is composed of the attenuated cytoplasm of pneumocytes, the basement membrane and thin cytoplasm of capillary endothelial cells.

[0091] The alveolar epithelium is composed of type I pneumocytes and type II pneumocytes, both of which are located on the basement membrane, and type II pneumocytes contribute to the interstitial organization and contain a portion of the interstitial fluid. The main function of type II pneumocytes is to form and secrete surfactant.

[0092] The tight junctions of the epithelial cells can be disrupted, allowing leakage of interstitial fluid, proteins, and even cells into the alveoli, thereby impairing breathing.

[0093] In acute respiratory failure, the epithelial barrier function of the lung is impaired, resulting in increased capillary permeability, leading to intra-alveolar fluid accumulation. BPD, ARDS, and IRDS are characterized by damage to the capillary endothelium and alveolar epithelium, which is associated with an impaired ability to remove fluid from the alveolar space and the accumulation of protein-rich fluid inside the alveoli.

[0094] The present invention describes for the first time the use of AF for restoring and / or normalizing the epithelial cell barrier, thereby effectively restoring and / or normalizing the epithelial barrier function in patients with acute respiratory failure (such as but not limited to BPD, IRDS and / or ARDS, acute ARDS, severe ARDS, acute pulmonary edema and interstitial pulmonary edema).

[0095] As shown in Example 1, adult pigs with experimentally induced ARDS treated with intravenous (iv) infusion of peptide AF-16 showed significantly reduced deleterious accumulation of fluid in alveolar and interstitial tissues ( Figure 3 ). In addition, the beneficial effects were evident within 1 hour and lasted significantly for at least 4 hours.

[0096] Example 1 further demonstrates that AF-16 treatment reduces structural abnormalities caused by induced traumatic lung injury compared to those recorded in vehicle-treated reference animals and demonstrates that no adverse side effects are shown with respect to cardiovascular parameters including blood pressure and heart rate.

[0097] The available results strongly suggest that AF-16 treatment has a statistically significant beneficial effect on cardiac output in acute respiratory failure ( Figure 4 ).

[0098] Thus, the present invention is primarily concerned with the treatment of the respiratory and cardiovascular systems.

[0099] In the respiratory system, it is most important to separate the breathed air from the blood and interstitial fluid by tissues with a thickness in the range of a few tenths of a micron, so as to be able to adequately absorb and exchange oxygen and carbon dioxide. For the proper normal (i.e. healthy) function of the respiratory tract including the alveoli, only a minimum amount of liquid is allowed. Therefore, a large number of adverse medical conditions are associated with the harmful increase of the amount of liquid in the alveoli, which damages breathing and eventually leads to suffocation and / or drowning, which is cardiogenic (e.g. due to myocardial infarction and other cardiomyopathy, severe hypertonia, acute decompensated heart failure) or non-cardiogenic (e.g. ARF, lung trauma, ARDS, IRDS, BPD, inhalation injury, sepsis, pneumonia, fluid overload, drowning, kidney disease, liver disease, neurogenic diseases (e.g. cerebral hemorrhage, stroke, brain trauma)).

[0100] Leakage of fluid into the alveoli and accumulation of fluid impede respiration and oxygenation and further increase the cardiac burden due to disturbed circulation and accumulation of blood in the lungs, which is associated with severe morbidity and high mortality. Prolonged hypoxia and hypercapnia often lead to persistent neuropsychiatric adverse symptoms and neurological deficits in surviving patients. Therefore, long-term consequences can severely impair quality of life and shorten life span. Currently available treatment recommendations are mainly symptomatic and these treatments only reduce the dangerous accumulation of fluid, debris and inflammatory cells in the alveoli and airways to a limited extent.

[0101] Antisecretory factor (AF) proteins, peptides, derivatives thereof, homologues thereof and / or fragments thereof having equivalent functional activity, and / or pharmaceutically active salts thereof have been studied for their beneficial effects on pathological accumulation of fluid in the lungs and extrapulmonary parts of the respiratory system under the above conditions.

[0102] In general, the present invention relates to the surprising insight that antisecretory factors (AF) significantly resolve the accumulation of fluid in the respiratory system ( Figure 3 ) and has beneficial effects on the cardiovascular system ( Figure 4 There are currently no other known drugs that reduce fluid accumulation in the respiratory system, including the critical alveoli.

[0103] Thus, the present invention relates to the surprising discovery that AF can effectively regulate and / or normalize the abnormal activity of said transcellular fluid transfer in disturbed and / or pathological cells, thereby effectively normalizing the life-critical epithelial barrier function of the affected tissues and / or organs.

[0104] Therefore, the present invention relates to the use of an antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or its homologues and / or fragments thereof having equivalent activity and comprising the amino acid sequence as shown in SEQ ID NO: 2 (AF-6), and / or pharmaceutically active salts thereof, and / or foods and / or food supplements (enriched with and / or naturally enriched with said antisecretory factor (AF) protein and / or its homologues and / or fragments thereof), wherein the epithelial barrier function and / or endothelial barrier function is restored and / or normalized by restoring the epithelial barrier function and / or endothelial barrier function and / or normalizing the epithelial barrier function and / or endothelial barrier function, thereby being used to treat and / or prevent acute respiratory failure.

[0105] Antisecretory factor

[0106] Antisecretory factors are a class of proteins naturally present in vivo. Human antisecretory factor AF protein is a 41 kDa protein containing 382 to 288 amino acids when isolated from the pituitary gland. The active site for the beneficial effect on the restoration and / or normalization of epithelial cell barrier function according to the present invention can be located in the protein in the region close to the N-terminal portion of the protein, in particular it can be located at amino acids 1-163 of SEQ ID NO: 1, more specifically at amino acid positions 35-50 on the antisecretory factor (AF) protein sequence. It has been shown that the biological effect of AF is exerted by any peptide or polypeptide comprising at least 6 amino acids of the consensus sequence (corresponding to SEQ ID NO: 2 (AF-6)) or a modification thereof that does not change the function of the polypeptide and / or peptide.

[0107] The inventors have shown that antisecretory factors are homologous to a certain extent to proteins S5a and Rpn10, which constitute subunits of the 26S proteasome, a major component of all cells, more specifically in the 19S / PA 700 cap. In the present invention, antisecretory factor (AF) proteins are defined as a class of homologous proteins with the same functional properties. Antisecretory factors are also similar to angiocidin, another protein isoform known to bind to thrombospondin-1 and associated with cancer progression.

[0108] Homologues and fragments of the antisecretory factor (AF) protein and / or peptide according to the present invention all have similar biological activities. In the context of this article, homologues and fragments contain at least 6 amino acids corresponding to those of the naturally occurring antisecretory factor (AF) protein (as shown in SEQ ID NO: 2), which can be further modified by changing one or more amino acids to optimize the biological activity of the antisecretory factor without changing the basic function of the polypeptide and / or peptide.

[0109] The antisecretory factor fragment and / or derivative according to the present invention may comprise an N-terminal protecting group and / or a C-terminal protecting group. An example of an N-terminal protecting group includes an acetyl group. An example of a C-terminal protecting group includes an amide.

[0110] In addition, any amino acid sequence having at least 70% identity (e.g., at least 72%, 75%, 77%, 80%, 82%, 85%, 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to the amino acid sequence of an antisecretory factor (AF) protein, peptide, homolog, derivative and / or fragment according to the invention is also considered to be within the scope of the invention.

[0111] A protein, homologue, peptide and / or fragment thereof having an amino acid sequence that is at least, for example, 95% identical to a reference amino acid sequence means that, for example, the amino acid sequence of a peptide is identical to the reference sequence, except that the amino acid sequence may include up to 5 point mutations per 100 amino acids of the reference amino acid sequence. That is, in order to obtain a polypeptide having an amino acid sequence that is at least 95% identical to a reference amino acid sequence, up to 5% of the amino acids in the reference sequence may be deleted or substituted with another amino acid, or a plurality of amino acids, up to 5% of all amino acids in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the amino or carboxyl terminal positions of the reference amino acid sequence, or at any position between these terminal positions (between any individually interspersed amino acids of the reference sequence), or in one or more consecutive groups within the reference sequence.

[0112] In the present invention, local algorithms are best suited for determining identity. Local algorithms (e.g., Smith Waterman) compare subsequences in one sequence to subsequences in a second sequence and find combinations of subsequences and alignments of these subsequences that yield the highest overall similarity score. Internal gaps are penalized if allowed. Local algorithms work well in comparing two multi-domain proteins that have a single domain in common or just binding sites.

[0113] The method for measuring identity and similarity is encoded in publicly available programs. Preferred computer program methods for measuring identity and similarity between two sequences include but are not limited to GCG program packages (Devereux, J et al. (1994)) BLASTP, BLASTN and FASTA (Altschul, SF et al. (1990)). The BLASTX program is publicly available from NCBI and other sources (BLAST Manual, Altschul, SF et al., Altschul, SF et al. (1990)). Each sequence analysis program has a default scoring matrix and a default gap penalty. Usually, molecular biologists will expect to use the default settings established by the software program used.

[0114] Antisecretory factor (AF) proteins or peptides as defined herein or homologues and / or fragments thereof with equivalent activity may comprise 6 amino acids or more, such as 6 to 16 amino acids, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids or more. In other preferred embodiments, the antisecretory factor is composed of 42, 43, 45, 46, 51, 80, 128, 129 or 163 amino acids. In a preferred embodiment, the antisecretory factor (AF) protein, its homologue, its peptide and / or fragment thereof according to the present invention is composed of 6, 7, 8 or 16 amino acids.

[0115] The antisecretory factor (AF) protein, its homologue, its peptide and / or its fragment according to the invention can be produced in vivo or in vitro, for example recombinantly, synthetically and / or chemically synthesized, and / or isolated from a naturally occurring source of antisecretory factor (e.g. from the porcine pituitary gland or bird eggs). After production, the antisecretory factor (AF) protein, its homologue, its peptide and / or its fragment according to the invention can be further processed, for example by chemical cleavage or enzymatic cleavage to smaller antisecretory active fragments or by modification of amino acids. It is currently not possible to obtain the antisecretory factor (AF) protein in pure form by purification. However, as previously disclosed in WO 97 / 08202 and WO 05 / 030246, biologically active antisecretory factor proteins can be produced recombinantly or synthetically. WO 97 / 08202 also discloses the production of biologically active fragments of the protein having 7 to 80 amino acids.

[0116] The antisecretory factor (AF) protein, its homologue, its peptide and / or its fragment according to the present invention may also contain an N-terminal protecting group and / or a C-terminal protecting group. An example of an N-terminal protecting group includes an acetyl group. An example of a C-terminal protecting group includes an amide.

[0117] In a preferred embodiment of the invention, the antisecretory factor (AF) protein, its homologue, its peptide and / or its fragment according to the invention is selected from SEQ ID NO 1-6, i.e. VCHSKTRSNPENNVGL (SEQ ID NO 3, also referred to as AF-16 in this context), IVCHSKTR (SEQ ID NO 5), VCHSKTR (SEQ ID NO 4), CHSKTR (SEQ ID NO 2), HSKTR (SEQ ID NO 6) or the amino acid sequence of the antisecretory factor (AF) protein according to SEQ ID NO 1, using common one-letter abbreviations to represent the amino acids. They have been previously disclosed, for example, in WO 05 / 030246. As indicated in the attached sequence listing listed, some of the amino acids in the sequences indicated above may be substituted by other amino acids. In the following of this paragraph, the position of a particular amino acid in a particular amino acid sequence is counted from the left, indicating that the most N-terminal amino acid is in position 1 in this particular sequence. Any amino acid substitution as indicated below may be made independently of any other amino acid substitution in this sequence. In SEQ ID NO 3, C in position 2 may be replaced by S, H in position 3 may be replaced by R or K, S in position 4 may be replaced by L, and / or T in position 6 may be replaced by A. In SEQ ID NO 5, C in position 3 may be replaced by S, H in position 4 may be replaced by R or K, S in position 5 may be replaced by L, and / or T in position 7 may be replaced by A. In SEQ ID NO 4, C in position 2 may be replaced by S, H in position 3 may be replaced by R or K, S in position 4 may be replaced by L, and / or T in position 6 may be replaced by A. In SEQ ID NO 2, C in position 1 may be replaced by S, H in position 2 may be replaced by R or K, S in position 3 may be replaced by L, and / or T in position 5 may be replaced by A. In SEQ ID NO 6, H in position 1 may be replaced by R or K, S in position 2 may be replaced by L, and / or T in position 4 may be replaced by A.

[0118] The present invention also contemplates combinations of two or more of any fragments / peptides according to SEQ ID NOs: 1-6.

[0119] The specific antisecretory factor (AF) protein or peptide to be used according to the present invention and / or comprised by the present invention is selected from the group consisting of an antisecretory factor (AF) protein comprising the amino acid sequence as shown in SEQ ID NO: 1, an antisecretory factor (AF) protein comprising the amino acid sequence as shown in SEQ ID NO: 2, an antisecretory factor (AF) protein comprising the amino acid sequence as shown in SEQ ID NO: 3, an antisecretory factor (AF) protein comprising the amino acid sequence as shown in SEQ ID NO: 4, and an antisecretory factor (AF) protein comprising the amino acid sequence as shown in SEQ ID NO: 5.

[0120] In addition, in another embodiment, the present invention relates to the use of an antisecretory factor (AF) protein (the antisecretory factor (AF) protein is a protein having an amino acid sequence as shown in SEQ ID NO: 1) or a homologue thereof, a derivative thereof and / or a fragment thereof comprising amino acids 37-42 of SEQ ID NO: 1.

[0121] In another embodiment, the present invention relates to the use of a pharmaceutical composition as disclosed herein, comprising two or more antisecretory factor (AF) proteins selected from the group consisting of proteins disclosed as SEQ ID NO: 1-6, and proteins disclosed as SEQ ID NO: 1, or homologues thereof, derivatives thereof and / or fragments thereof comprising amino acids 37-42 of SEQ ID NO: 1, or sequences disclosed as the general formula as described herein. All of said sequences are also preferably used in the present invention.

[0122] WO 00 / 038535 discloses food products enriched with and / or naturally rich in antisecretory factor (AF) protein, which are examples of suitable foods, foodstuffs and / or food supplements used in the context of this article. Another example used in this context is egg yolk, which contains at least 0.05 ng / ml of an antisecretory factor (AF) protein fragment having an amino acid sequence as disclosed in SEQ ID NO: 3 and / or SEQ ID NO: 4 (e.g. disclosed in WO 2017 / 009004).

[0123] Pharmaceutical composition

[0124] In one embodiment of the invention, the pharmaceutical composition according to the present invention also comprises a pharmaceutically acceptable excipient. The selection of pharmaceutically acceptable excipients and their optimum concentrations used according to the present invention can be easily determined by the technician through experiments. The pharmaceutically acceptable excipients used according to the present invention include solvents, buffers, preservatives, chelating agents, antioxidants and stabilizers, emulsifiers, suspending agents and / or diluents. The pharmaceutical composition of the present invention can be prepared according to conventional pharmaceutical practices, for example, according to "Remington:The science and practice of pharmacy", 21st edition, ISBN 0-7817-4673-6 or "Encyclopedia of pharmaceutical technology", 2nd edition, Swarbrick J. edited, ISBN:0-8247-2152-7.

[0125] Pharmaceutically acceptable excipients are substances that are substantially harmless to the individual to whom the composition is to be administered. Such excipients generally meet the requirements set by national health authorities. Official pharmacopoeias such as the British Pharmacopoeia, the United States Pharmacopoeia, and the European Pharmacopoeia set standards for pharmaceutically acceptable excipients.

[0126] The following is a review of the relevant compositions optionally used in the pharmaceutical compositions according to the present invention. The review is based on a specific route of administration. However, it should be understood that in those cases where a pharmaceutically acceptable excipient can be used in different dosage forms or compositions, the application of a specific pharmaceutically acceptable excipient is not limited to a specific dosage form or has a specific function of the excipient. It should be emphasized that the present invention is not limited to the use of the compositions mentioned below.

[0127] Parenteral Composition:

[0128] For systemic administration, the compositions according to the present invention may contain conventional non-toxic pharmaceutically acceptable carriers and excipients, including microspheres and liposomes.

[0129] Compositions for use according to the present invention may include all kinds of solid, semi-solid and fluid compositions.

[0130] Pharmaceutically acceptable excipients may include solvents, buffers, preservatives, chelating agents, antioxidants and stabilizers, emulsifiers, suspending agents and / or diluents. Examples of different agents are given below.

[0131] Examples of various reagents:

[0132] Examples of solvents include, but are not limited to, water, alcohol, blood, plasma, cerebrospinal fluid, ascites, and lymph fluid.

[0133] Examples of buffers include, but are not limited to, citric acid, acetic acid, tartaric acid, lactic acid, hydrogenphosphoric acid, bicarbonate, phosphate, diethylamide, and the like.

[0134] Examples of chelating agents include, but are not limited to, EDTA and citric acid.

[0135] Examples of antioxidants include, but are not limited to, butylated hydroxyanisole (BHA), ascorbic acid and its derivatives, tocopherol and its derivatives, cysteine, and mixtures thereof.

[0136] Examples of diluents and disintegrants include, but are not limited to, lactose, sucrose, emdex, calcium phosphate, calcium carbonate, calcium sulfate, mannitol, starch, and microcrystalline cellulose.

[0137] Examples of binders include, but are not limited to, sucrose, sorbitol, gum arabic, sodium alginate, gelatin, chitosan, starch, cellulose, carboxymethyl cellulose, methyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, and polyethylene glycol.

[0138] The pharmaceutical composition according to the invention is administered topically in one case or by intravenous infusion or infusion into a central blood vessel or a blood vessel or duct associated with an organ, or by intramuscular or subcutaneous injection into the patient, or by buccal, pulmonary, nasal, transdermal or oral routes. In addition, the pharmaceutical composition may also be administered into the brain parenchyma or cerebral ventricles or spaces within or around the nervous system of the patient via a surgically inserted shunt.

[0139] In one embodiment, the pharmaceutical composition used according to the present invention is formulated for intraocular, topical, intranasal, oral, dermal, subcutaneous and / or systemic administration. The selected route of administration will vary depending on the condition of the patient to be treated and the age and sex of the patient, etc.

[0140] In a preferred embodiment, the composition of the invention is administered by application as a suspension or even more preferably as a powder for inhalation through the nose and / or to the respiratory tract using a nebulizer, aerosol, inhaler or atomizer.

[0141] The use of powders comprising antisecretory factors has additional advantages in terms of stability and dosage. The pharmaceutical composition according to the present invention can also be applied topically, administered systemically through the eye, nose, mouth, skin, subcutaneously and / or via blood vessels. In a preferred embodiment, the pharmaceutical composition is formulated for intravenous, intramuscular, topical, oral or nasal administration. Typically, when used for topical administration to the eyes, the composition of the present invention is applied at a concentration of 1 μg to 1 mg, preferably 50 μg to 5000 μg, in a single daily dose or repeated several times (multiple doses) per day, but is not limited thereto.

[0142] For systemic administration to the blood, the dosage is 0.1 μg to 10 mg per kg body weight per administration, for example 0.1 μg to 100 mg per kg body weight per administration, preferably 1 to 5000 μg / kg body weight, such as 1 to 10000 μg / kg body weight. When egg yolk enriched with and / or naturally rich in antisecretory factors is used according to the invention, the preparation is preferably administered orally via a tube and / or feeding tube.

[0143] In one embodiment of the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. Such excipients may be any preferred excipient selected to be suitable for a particular purpose. Examples of excipients are disclosed herein.

[0144]

[0145] The present invention also relates to egg yolks enriched with and / or naturally enriched with antisecretory factor (AF) protein, currently marketed under the trademark The invention relates to the use of egg yolk for the preparation of food and / or food supplements enriched with and / or naturally enriched with the antisecretory factor (AF) protein and / or its homologues and / or fragments thereof, which are used to restore and / or normalize the epithelial barrier function in the pathogenesis of acute respiratory failure, such as but not limited to the treatment of patients with abnormal accumulation of fluid in the alveoli and bronchioles, acute respiratory failure, ARDS (acute respiratory distress syndrome), IRDS (infant respiratory distress syndrome), SIRS (systemic inflammatory response syndrome), other severe systemic inflammatory diseases and / or cardiovascular pulmonary diseases.

[0146] The present invention also relates to a food and / or food supplement enriched with and / or naturally enriched with said antisecretory factor (AF) protein and / or its homologues and / or fragments thereof, wherein said food and / or food supplement enriched with and / or naturally enriched with said antisecretory factor (AF) protein and / or its homologues and / or fragments thereof is provided as egg yolk enriched with and / or naturally enriched with antisecretory factors (e.g. egg yolk enriched with naturally occurring antisecretory factors (NASPs) as disclosed in WO 00 / 038535), for use in restoring and / or normalizing epithelial barrier function in the pathogenesis of acute respiratory failure (ARF), for example but not limited to the treatment of patients suffering from abnormal accumulation of fluid in the alveoli and bronchioles, BPD, ARDS, IRDS, sepsis, SIRS (systemic inflammatory response syndrome), other severe systemic inflammatory diseases and / or cardiovascular pulmonary diseases.

[0147] The present invention also relates to foods and / or food supplements enriched with and / or naturally enriched in antisecretory factor (AF) protein and / or its homologues and / or fragments thereof, which are provided in egg yolk comprising at least 0.05 ng / ml of an antisecretory factor (AF) protein fragment having an amino acid sequence as disclosed in SEQ ID NO 3 and / or SEQ ID NO 4 (e.g. disclosed in WO 2017 / 009004), for use in restoring and / or normalizing epithelial barrier function in the pathogenesis of acute respiratory failure (ARF), for example but not limited to the treatment of patients with abnormal accumulation of fluid in the alveoli and bronchioles, BPD, ARDS, IRDS, sepsis, SIRS (systemic inflammatory response syndrome), other severe systemic inflammatory diseases and / or cardiovascular pulmonary diseases.

[0148] The egg yolk compositions enriched and / or naturally enriched with antisecretory factor (AF) protein and / or homologues and / or fragments thereof (e.g. disclosed in WO 00 / 038535 or WO 2017 / 009004) for the uses described herein and incorporated herein by reference can be provided as a food, a food supplement, a pharmaceutical composition and / or as a medical food.

[0149] Treatment

[0150] The present invention also relates to the treatment of acute respiratory failure (ARF), such as but not limited to the treatment of patients suffering from abnormal accumulation of fluid in the alveoli and bronchioles, BPD, ARDS, IRDS, sepsis, SIRS and / or cardiovascular pulmonary disease, by administering to a patient in need thereof an antisecretory factor (AF) protein and / or its homologues and / or fragments thereof and / or pharmaceutically active salts thereof and / or food and / or food supplement (enriched with and / or naturally enriched with the antisecretory factor (AF) protein and / or its homologues and / or fragments thereof), in a pharmaceutical composition and / or medical food, the pharmaceutical composition and / or medical food being formulated for systemic administration to the blood at a dose of 0.1 μg to 100 mg per kg of body weight per administration, preferably 1 μg to 10000 μg per kg of body weight per administration, and wherein the administration is carried out as a single dose or multiple administrations per day.

[0151] The present invention also relates to a method for treating, preventing and / or prophylactically treating acute respiratory failure (ARF), for example but not limited to treating patients suffering from abnormal accumulation of fluid in the alveoli and bronchioles, BPD, ARDS, IRDS, sepsis, SIRS and / or cardiovascular pulmonary disease, wherein an antisecretory factor (AF) protein as shown in SEQ ID NO: 1 (AF) and / or a homologue and / or fragment thereof comprising the amino acid sequence as shown in SEQ ID NO: 2 (AF-6), and / or a pharmaceutically active salt thereof, and / or a food and / or food supplement enriched with and / or naturally enriched with the antisecretory factor (AF) protein and / or its homologue and / or fragment thereof is administered to a mammal in need thereof in an amount sufficient to restore and / or normalize the epithelial cell barrier function.

[0152] The present invention also relates to methods for treating, preventing and / or prophylactically treating acute respiratory failure (ARF), such as, but not limited to, treating patients suffering from abnormal accumulation of fluid in the alveoli and bronchioles, BPD, ARDS, IRDS, sepsis, SIRS and / or cardiovascular pulmonary disease.

[0153] Experimental Section

[0154] Example 1

[0155] ARDS model based on airway lavage and noxious ventilation

[0156] background

[0157] The aim of this experiment was to elucidate the effects of peptide AF-16 administered to adult pigs with experimentally induced ARDS.

[0158] Experimental setup

[0159] After ethical approval, a total of 12 3-month-old pigs (weight 30-35 kg) were purchased from a local farm and brought to the laboratory 2 pigs each in 6 batches on the morning of the experiment. Two pigs were used in parallel, one randomly assigned to be treated with AF-16, while the other received vehicle sterile saline. Upon arrival, the pigs were sedated and then kept fully anesthetized throughout the experiment until termination later that day. A tracheostomy was performed and mechanical ventilation was used using a ventilator. This setup Figure 1 The tubes are located in the arteries, veins and also in the right heart through the veins. The device is implanted to enable the use of the PiCCO instrument (Pulse Index, Continuous Cardiac Output = PiCCO) so that the total blood volume in the lungs, extravascular lung water (EVLW) and cardiac function parameters can be accurately determined. A blood pressure sensor is inserted into the pulmonary artery and central artery. Arterial blood gases and other blood parameters are checked at regular intervals. Hemoglobin oxygen saturation in arterial blood is determined by hemoximetry. Core body temperature is automatically maintained at the desired normal level. An EKG is recorded. All instruments are connected to a critical care control panel and computer to enable continuous recording and retrieval of saved data. Fluids are infused intravenously (iv) under strict control to avoid overhydration. The prescribed precautions and treatments keep the animals in good condition.

[0160] After stabilization, lung injury is induced by flushing temperature-controlled saline in the bronchial tree, which causes surfactant depletion and collapse-prone lungs. This is followed by 1 hour of injurious ventilation (i.e. ventilation with high inspiratory and low end expiratory airway pressures), which causes traumatic lung damage at the alveolar level. The parameters of the mechanical ventilation are adjusted with the aid of a ventilator. Within 1 hour, the amount of fluid accumulated in the alveoli increases, which, even at an early stage, severely reduces oxygen uptake and impedes carbon dioxide excretion.

[0161] Treatment with peptide AF-16 or vehicle was started after induction of lung injury (i.e. after noxious ventilation). AF-16 dissolved in saline was infused intravenously over 10 minutes into one of the two pigs participating in each experiment and day. The second pig was infused with vehicle at the same time. The laboratory personnel involved in the experiment did not know which animal received the drug to be tested and which animal received the vehicle, and the code was not available until after all experiments. PiCCO values ​​were measured every hour until 4 hours after infusion of the test substance. The experiment was finally terminated, the animals were euthanized and autopsied.

[0162] The PiCCO system is used to measure with high precision the extravascular lung water (EVLW), which is the water present in the alveoli and interstitial tissues, excluding the lung blood volume. The presence of fluid in the alveolar lumen reduces the amount of air in each alveolus and further increases the distance, thereby hindering or even eliminating the oxygen / carbon dioxide exchange between the breathing air and the blood in the pulmonary capillaries, leading in particular to hypoxemia. Edema itself will also exacerbate ventilator-induced lung injury and inflammation (the ventilator will induce lung injury through the positive pressure delivered to the lungs) and initiate a vicious cycle that increases inflammation and the likelihood of developing sepsis. This inflammatory response will then spread systemically and lead to cell death in multiple organs and tissues. In fact, the most common cause of death in ARDS is multi-organ failure due to this cause.

[0163] result

[0164] (See Figure 3 )

[0165] At the start of the experiment, the EVLW volume was approximately 330 ml (average of 6 pigs treated with AF-16 and 6 pigs with vehicle) as determined by the PiCCO system. The average weight of the pigs was approximately 35 kg.

[0166] Lung damage was induced by flushing the airways with bland saline, resulting in an increase in EVLW to 500 ml to 520 ml after 1 hour, as determined in 6 pigs intended to be treated with AF-16 and 6 pigs that received vehicle only.

[0167] Infusion of 2 mg / kg body weight of AF-16 resulted in a decrease in EVLW within 1 hour, to 460 ml, which was statistically significantly different from the 510 mL EVLW demonstrated by the 6 vehicle-treated pigs.

[0168] At 2 hours after AF-16 infusion, the mean EVLW of the six pigs treated with AF-16 decreased to 430 ml, which was significantly different from the 505 mL measured in the vehicle group.

[0169] Three hours after treatment with AF-16, the EVLW volume of these six pigs was even lower (420 ml), which was significantly different from the 500 mL measured in the vehicle group.

[0170] After 4 hours, the EVLW content of AF-16 treated pigs was 400 ml, which was still significantly different from the EVLW content of 480 ml in vehicle treated pigs.

[0171] Lungs of pigs were photographed at necropsy 5 hours after induction of lung damage and after a single infusion of AF-16 or vehicle (saline) treatment within 4 hours. Figure 2As shown. The AF-16 treated lungs showed a near normal appearance with minimal hemorrhage in both left and right lobes. In contrast, the lungs of the six pigs treated with vehicle showed extensive atelectasis and hemorrhage, causing tissue discoloration and appearing dark bilaterally. Only limited areas of the upper portion of the vehicle treated lungs had a normal appearance, indicating that the functional capacity of the vehicle lungs was limited. The vehicle treated lungs became heavy and swollen, resulting in a pressure hemorrhage pattern in the thoracocostal cavity becoming visible ( Figure 3 ).

[0172] Furthermore, in ALI pigs treated with AF-16, cardiac output (CO) remained almost at the same level as the initial baseline value ( Figure 4 ). In contrast, vehicle infusion kept CO at a fairly low level. The increased CO can be explained by normalized pulmonary vascular resistance due to less pulmonary edema. In this model, pulmonary edema leads to increased alveolar vascular compression and pulmonary vasoconstriction, which increases pulmonary vascular resistance and impairs flow through the lungs, thereby impairing CO.

[0173] in conclusion

[0174] The main conclusion is that intravenous infusion of the peptide AF-16 significantly reduces the harmful accumulation of fluid in alveolar and interstitial tissues in experimentally injured lungs, and the beneficial effects are evident within 1 hour and persist for at least 3 to 4 hours.

[0175] With regard to cardiovascular parameters including blood pressure and heart rate, no adverse side effects were shown.

[0176] The available results indicate a beneficial effect of AF-16 on cardiac output, i.e. an improvement in cardiac function. This observation is important, since right heart failure is not uncommon in acute lung disease.

[0177] References

[0178] 1. Lange, S., and I.2001.The antisecretory factor:synthesis,anatomical and cellular distribution,and biological action in experimental and clinical studies.Int.Rev.Cytol.210,39-75.

[0179] 2. H.-A. Hansson, M. Al-Olama, E. Jennische, K. Gatzinsky and S. Lange (2012). The peptide AF-16 and the AF protein counteract intracranial hypertension. Acta Neurochir. Suppl. 114, 377-382.

[0180] 3. Remington: The science and practice of pharmacy”, 21st Edition, ISBN 0-7817-4673-6 or “Encyclopedia of pharmaceutical technology”, 2nd Edition, Swarbrick J. editor, ISBN: 0-8247-2152-7.

[0181] 4. WO 97 / 08202

[0182] 5. WO 05 / 030246

[0183] 6. WO 97 / 08202

[0184] 7. WO 97 / 08202

[0185] 8. WO 98 / 21978

[0186] 9. WO 00 / 038535

[0187] 10. WO 05 / 030246

[0188] 11. WO 07 / 126364

[0189] 12. WO 07 / 126363

[0190] 13. WO 07 / 126365

[0191] 14. WO 2010 / 093324

[0192] 15. Sakka S.G. Extravascular lung water in ARDS patients. Minerva Anestesiol. 2013; 79:274-284.

[0193] 16. Singer M, Deutschman C S, Seymore C W, et al., The third international consensus definitions for sepsis and septic shock [Sepsis-3]. JAMA 2016; 315: 801-810.

[0194] 17. Calfee, et al., Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders, Crit Care Med. 2009.

[0195] 18. Claesson J, Freundlich M, Gunnarsson I, Laake JH, M H, et al., Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome. Acta Anaesth Scand 2016; 60: 697-709.

[0196] 19. Huppert LA and Matthay MA. Alveolar Fluid Clearance in Pathologically Relevant Conditions: In Vitro and In Vivo Models of Acute Respiratory Distress Syndrome. Front. Immunol. 2017; 8: 371. doi: 10.3389 / fimmu.2017.00371.

[0197] 20. Altschul, S.F., Gish, W., Miller, W., Myers, E.w., Lipman, D.J. Basic local alignment search tool. Journal of Molecular Biology 1990; 215 / 3: 403-410. Sequence Listing <110> Rand Menne Medical <120> Use of antisecretory factors in the treatment and / or prevention of acute respiratory failure <130> PS55201SE00 <160> 6 <170> Windows FastSEQ Version 4.0 <210> 1 <211> 382 <212> PRT <213> people <400> 1 Met Val Leu Glu Ser Thr Met Val Cys Val Asp Asn Ser Glu Tyr Met 1 5 10 15 Arg Asn Gly Asp Phe Leu Pro Thr Arg Leu Gln Ala Gln Gln Asp Ala 20 25 30 Val Asn Ile Val Cys His Ser Lys Thr Arg Ser Asn Pro Glu Asn Asn 35 40 45 Val Gly Leu Ile Thr Leu Ala Asn Asp Cys Glu Val Leu Thr Thr Leu 50 55 60 Thr Pro Asp Thr Gly Arg Ile Leu Ser Lys Leu His Thr Val Gln Pro 65 70 75 80 Lys Gly Lys Ile Thr Phe Cys Thr Gly Ile Arg Val Ala His Leu Ala 85 90 95 Leu Lys His Arg Gln Gly Lys Asn His Lys Met Arg Ile Ile Ala Phe 100 105 110 Val Gly Ser Pro Val Glu Asp Asn Glu Lys Asp Leu Val Lys Leu Ala 115 120 125 Lys Arg Leu Lys Lys Glu Lys Val Asn Val Asp Ile Ile Asn Phe Gly 130 135 140 Glu Glu Glu Val Asn Thr Glu Lys Leu Thr Ala Phe Val Asn Thr Leu 145 150 155 160 Asn Gly Lys Asp Gly Thr Gly Ser His Leu Val Thr Val Pro Pro Gly 165 170 175 Pro Ser Leu Ala Asp Ala Leu Ile Ser Ser Pro Ile Leu Ala Gly Glu 180 185 190 Gly Gly Ala Met Leu Gly Leu Gly Ala Ser Asp Phe Glu Phe Gly Val 195 200 205 Asp Pro Ser Ala Asp Pro Glu Leu Ala Leu Ala Leu Arg Val Ser Met 210 215 220 Glu Glu Gln Arg His Ala Gly Gly Gly Ala Arg Arg Ala Ala Arg Ala 225 230 235 240 Ser Ala Ala Glu Ala Gly Ile Ala Thr Thr Gly Thr Glu Asp Ser Asp 245 250 255 Asp Ala Leu Leu Lys Met Thr Ile Ser Gln Gln Glu Phe Gly Arg Thr 260 265 270 Gly Leu Pro Asp Leu Ser Ser Met Thr Glu Glu Glu Gln Ile Ala Tyr 275 280 285 Ala Met Gln Met Ser Leu Gln Gly Ala Glu Phe Gly Gln Ala Glu Ser 290 295 300 Ala Asp Ile Asp Ala Ser Ser Ala Met Asp Thr Ser Glu Pro Ala Lys 305 310 315 320 Glu Glu Asp Asp Tyr Asp Val Met Gln Asp Pro Glu Phe Leu Gln Ser 325 330 335 Val Leu Glu Asn Leu Pro Gly Val Asp Pro Asn Asn Glu Ala Ile Arg 340 345 350 Asn Ala Met Gly Ser Leu Pro Pro Arg Pro Pro Arg Thr Ala Arg Arg 355 360 365 Thr Arg Arg Arg Lys Thr Arg Ser Glu Thr Gly Gly Lys Gly 370 375 380 <210> 2 <211> 6 <212> PRT <213> Artificial sequence <220> <221> Variants <222> 5 <223> Can be replaced by A <221> Variants <222> 2 <223> Can be replaced by R or K <221> Variants <222> 3 <223> Can be replaced by L <221> Variants <222> 1 <223> Can be replaced by S <400> 2 Cys His Ser Lys Thr Arg 1 5 <210> 3 <211> 16 <212> PRT <213> Artificial sequence <220> <221> Variants <222> 6 <223> Can be replaced by A <221> Variants <222> 3 <223> Can be replaced by R or K <221> Variants <222> 4 <223> Can be replaced by L <221> Variants <222> 2 <223> Can be replaced by S <400> 3 Val Cys His Ser Lys Thr Arg Ser Asn Pro Glu Asn Asn Val Gly Leu 1 5 10 15 <210> 4 <211> 7 <212> PRT <213> Artificial sequence <220> <221> Variants <222> 6 <223> Can be replaced by A <221> Variants <222> 3 <223> Can be replaced by R or K <221> Variants <222> 4 <223> Can be replaced by L <221> Variants <222> 2 <223> Can be replaced by S <400> 4 Val Cys His Ser Lys Thr Arg 1 5 <210> 5 <211> 8 <212> PRT <213> Artificial sequence <220> <221> Variants <222> 7 <223> Can be replaced by A <221> Variants <222> 4 <223> Can be replaced by R or K <221> Variants <222> 5 <223> Can be replaced by L <221> Variants <222> 3 <223> Can be replaced by S <400> 5 Ile Val Cys His Ser Lys Thr Arg 1 5 <210> 6 <211> 5 <212> PRT <213> Artificial sequence <220> Active Peptides <221> Variants <222> 1 <223> Can be replaced by R or K <221> Variants <222> 2 <223> Can be replaced by L <221> Variants <222> 4 <223> Can be replaced by A <400> 6 His Ser Lys Thr Arg 1 5

Claims

1. Use of the antisecretory factor peptide AF-16 composed of amino acids VCHSKTRSNPENNVGL and / or its pharmaceutically active salts for preparing a pharmaceutical composition for treating and / or preventing acute respiratory failure ARF.

2. The use according to claim 1, for preparing a pharmaceutical composition for treating and / or preventing acute respiratory failure in patients with abnormal accumulation of fluid in the alveoli and / or bronchioles, wherein the patients are selected from patients suffering from bronchopulmonary dysplasia BPD, acute respiratory distress syndrome ARDS, infant respiratory distress syndrome IRDS, sepsis, systemic inflammatory response syndrome SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular lung disease.

3. The use according to claim 1 or 2, for preparing a pharmaceutical composition for treating and / or preventing BPD, IRDS or ARDS, wherein: ARDS was selected from the group consisting of acute ARDS and severe ARDS.

4. The use according to claim 1, wherein The antisecretory factor peptide and / or its pharmaceutically active salt is formulated in a pharmaceutical composition comprising the antisecretory factor peptide and / or its pharmaceutically active salt and a pharmaceutically acceptable excipient.

5. The use according to claim 1, wherein The pharmaceutical composition is formulated for intraocular, intranasal, oral and / or subcutaneous administration.

6. The use according to claim 1, wherein The pharmaceutical compositions are formulated for local and / or systemic administration.

7. The use according to claim 1, wherein The pharmaceutical composition is formulated for administration as a spray, an aerosol, an inhaler.

8. The use according to claim 1, wherein The pharmaceutical composition is formulated for administration by nebulizer.

9. The use according to claim 1, wherein The pharmaceutical composition is formulated for systemic administration to the blood at a dose of 0.1 μg to 100 mg per kg body weight per administration, and wherein the administration is performed as a single dose or in multiple administrations per day.

10. The use according to claim 9, wherein The pharmaceutical composition is formulated for systemic administration to the blood at a dose of 1 μg to 10000 μg per kg body weight per administration.

11. A pharmaceutical composition comprising the antisecretory factor peptide AF-16 consisting of amino acids VCHSKTRSNPENNVGL and / or a pharmaceutically active salt thereof, wherein the pharmaceutical composition is used for treating and / or preventing acute respiratory failure.

12. A pharmaceutical composition according to claim 11 for use in the treatment and / or prevention of acute respiratory failure in patients with abnormal accumulation of fluid in the alveoli and / or bronchioles, the patients being selected from patients suffering from BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular pulmonary disease.